載入中
HeartSciences Inc. is a medical technology company dedicated to augmenting the clinical utility of electrocardiograms (ECGs) by integrating artificial intelligence (AI). The firm develops AI-enhanced ECG (AI-ECG) solutions, including an algorithm specifically designed to detect impaired cardiac relaxation or other forms of cardiac dysfunction, whether caused by heart disease or the natural aging process. Among its offerings is the MyoVista wavECG device, a 12-lead resting ECG that provides comprehensive diagnostic information concerning cardiac function alongside conventional ECG data in a single examination. Furthermore, the company offers MyoVista Insights, a cloud-based platform capable of hosting its AI-ECG algorithms across various ECG hardware systems. Established in 2007, HeartSciences Inc. operates from its headquarters in Southlake, Texas. The company was formerly named Heart Test Laboratories, Inc. until its rebranding to HeartSciences Inc. in October 2024.
前收盤價
US$3.18
+US$0.14 · +4.61%
盤中時間採用ET。市場資料可能有所延遲。
HeartSciences Inc. is a medical technology company dedicated to augmenting the clinical utility of electrocardiograms (ECGs) by integrating artificial intelligence (AI). The firm develops AI-enhanced ECG (AI-ECG) solutions, including an algorithm specifically designed to detect impaired cardiac relaxation or other forms of cardiac dysfunction, whether caused by heart disease or the natural aging process. Among its offerings is the MyoVista wavECG device, a 12-lead resting ECG that provides comprehensive diagnostic information concerning cardiac function alongside conventional ECG data in a single examination. Furthermore, the company offers MyoVista Insights, a cloud-based platform capable of hosting its AI-ECG algorithms across various ECG hardware systems. Established in 2007, HeartSciences Inc. operates from its headquarters in Southlake, Texas. The company was formerly named Heart Test Laboratories, Inc. until its rebranding to HeartSciences Inc. in October 2024.
日內區間
目前US$3.18
52週區間
目前US$3.18
盤中時間採用ET。市場資料可能有所延遲。
HeartSciences Inc. is a medical technology company dedicated to augmenting the clinical utility of electrocardiograms (ECGs) by integrating artificial intelligence (AI). The firm develops AI-enhanced ECG (AI-ECG) solutions, including an algorithm specifically designed to detect impaired cardiac relaxation or other forms of cardiac dysfunction, whether caused by heart disease or the natural aging process. Among its offerings is the MyoVista wavECG device, a 12-lead resting ECG that provides comprehensive diagnostic information concerning cardiac function alongside conventional ECG data in a single examination. Furthermore, the company offers MyoVista Insights, a cloud-based platform capable of hosting its AI-ECG algorithms across various ECG hardware systems. Established in 2007, HeartSciences Inc. operates from its headquarters in Southlake, Texas. The company was formerly named Heart Test Laboratories, Inc. until its rebranding to HeartSciences Inc. in October 2024.
日內區間
目前US$3.18
52週區間
目前US$3.18
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 營收 | 4319 USD | 4350 USD | 1.86萬 USD | 5150 USD | 1.44萬 USD |
| 銷貨成本 | 13.31萬 USD | 12.98萬 USD | 10.12萬 USD | 2.97萬 USD | 3.45萬 USD |
| 毛利 | −12.88萬 USD | −12.55萬 USD | −8.26萬 USD | −2.46萬 USD | −2.01萬 USD |
| 研究與開發 | 28.39億 USD | 438.61萬 USD | 287.86萬 USD | 246.09萬 USD | 300.15萬 USD |
| 銷售、一般及管理費用 | 55.76億 USD | 384.1萬 USD | 334.46萬 USD | 362.75萬 USD | 168.78萬 USD |
| 營業費用 | 828.41萬 USD | 822.71萬 USD | 622.32萬 USD | 608.84萬 USD | 468.93萬 USD |
| 利息收入 | — | 8.78萬 USD | — | — | — |
| 利息支出 | 75.3萬 USD | 50.05萬 USD | 35.41萬 USD | 24.32萬 USD | 37.16萬 USD |
| 折舊和攤銷 | 13.14萬 USD | 12.8萬 USD | 9.51萬 USD | 13.55萬 USD | 2.66萬 USD |
| 營業利益 | −841.29萬 USD | −835.26萬 USD | −630.58萬 USD | −611.3萬 USD | −470.94萬 USD |
| 淨利 | −914.19萬 USD | −876.52萬 USD | −660.52萬 USD | −635.43萬 USD | −482.83萬 USD |
公司資料更新於 2026年10月12日。
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
